OBJECTIVE: Ovarian cancer is the most lethal gynecological malignancy, but information relevant to prognosis and outcomes remain unknown. Here, we used statistical methods to focus specifically on interactions between candidate prognostic variables. METHODS AND RESULTS: Univariate, multivariate, and elastic net modeling of 42 variables were applied to a cohort of 542 ovarian cancer patients with 393 episodes of cancer recurrence/death. In univariate analyses, overexpression of TFF3, MDM2, and p53 were associated with improved recurrence-free survival. In multivariate analyses adjusted for age, histology, stage, grade, ascites, and residual disease, overexpression of PR appeared to provide a protective effect [hazard ratio for >50% of cells positive, 0.64 (95% confidence interval 0.44-0.94) compared to <1%], and TFF3 showed a nonlinear association. Importantly, we observed no interactions among variables. However, patients with tumors with moderate TFF3 expression were at a marginally increased risk of recurrence, and patients with tumors with high expression were at a similar to slightly lower risk, compared to those with tumors with no TFF3 expression. CONCLUSIONS: Although no interactions among variables were observed, this study provides important precedent for seeking interactions between clinical and tumor variables in future studies.
OBJECTIVE:Ovarian cancer is the most lethal gynecological malignancy, but information relevant to prognosis and outcomes remain unknown. Here, we used statistical methods to focus specifically on interactions between candidate prognostic variables. METHODS AND RESULTS: Univariate, multivariate, and elastic net modeling of 42 variables were applied to a cohort of 542 ovarian cancerpatients with 393 episodes of cancer recurrence/death. In univariate analyses, overexpression of TFF3, MDM2, and p53 were associated with improved recurrence-free survival. In multivariate analyses adjusted for age, histology, stage, grade, ascites, and residual disease, overexpression of PR appeared to provide a protective effect [hazard ratio for >50% of cells positive, 0.64 (95% confidence interval 0.44-0.94) compared to <1%], and TFF3 showed a nonlinear association. Importantly, we observed no interactions among variables. However, patients with tumors with moderate TFF3 expression were at a marginally increased risk of recurrence, and patients with tumors with high expression were at a similar to slightly lower risk, compared to those with tumors with no TFF3 expression. CONCLUSIONS: Although no interactions among variables were observed, this study provides important precedent for seeking interactions between clinical and tumor variables in future studies.
Authors: Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07-23 Impact factor: 4.254
Authors: Inger T Gram; Annekatrin Lukanova; Ilene Brill; Tonje Braaten; Eiliv Lund; Eva Lundin; Kim Overvad; Anne Tjønneland; Francoise Clavel-Chapelon; Nathalie Chabbert-Buffet; Christina Bamia; Antonia Trichopoulou; Dimosthenis Zylis; Giovanna Masala; Franco Berrino; Rocco Galasso; Rosario Tumino; Carlotta Sacerdote; Oxana Gavrilyuk; Steinar Kristiansen; Laudina Rodríguez; Catalina Bonet; José María Huerta; Aurelio Barricarte; Maria-José Sánchez; Miren Dorronsoro; Karin Jirström; Martin Almquist; Annika Idahl; H Bas Bueno-de-Mesquita; Marie Braem; Charlotte Onland-Moret; Konstantinos K Tsilidis; Naomi E Allen; Veronika Fedirko; E Riboli; Rudolf Kaaks Journal: Int J Cancer Date: 2011-09-14 Impact factor: 7.396
Authors: A Kjaerbye-Thygesen; K Frederiksen; E V Høgdall; C K Høgdall; J Blaakaer; S Krüger Kjaer Journal: Eur J Gynaecol Oncol Date: 2006 Impact factor: 0.196
Authors: Michael G Kelly; Ayesha B Alvero; Rui Chen; Dan-Arin Silasi; Vikki M Abrahams; Serena Chan; Irene Visintin; Thomas Rutherford; Gil Mor Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: M Köbel; J Madore; S J Ramus; B A Clarke; P D P Pharoah; S Deen; D D Bowtell; K Odunsi; U Menon; C Morrison; S Lele; W Bshara; L Sucheston; M W Beckmann; A Hein; F C Thiel; A Hartmann; D L Wachter; M S Anglesio; E Høgdall; A Jensen; C Høgdall; K R Kalli; B L Fridley; G L Keeney; Z C Fogarty; R A Vierkant; S Liu; S Cho; G Nelson; P Ghatage; A Gentry-Maharaj; S A Gayther; E Benjamin; M Widschwendter; M P Intermaggio; B Rosen; M Q Bernardini; H Mackay; A Oza; P Shaw; M Jimenez-Linan; K E Driver; J Alsop; M Mack; J M Koziak; H Steed; C Ewanowich; A DeFazio; G Chenevix-Trench; S Fereday; B Gao; S E Johnatty; J George; L Galletta; E L Goode; S K Kjær; D G Huntsman; P A Fasching; K B Moysich; J D Brenton; L E Kelemen Journal: Br J Cancer Date: 2014-10-30 Impact factor: 7.640
Authors: Andrea E Wahner Hendrickson; Kieran M Hawthorne; Ellen L Goode; Kimberly R Kalli; Krista M Goergen; Jamie N Bakkum-Gamez; William A Cliby; Gary L Keeney; Daniel W Visscher; Yaman Tarabishy; Ann L Oberg; Lynn C Hartmann; Matthew J Maurer Journal: Gynecol Oncol Date: 2015-01-22 Impact factor: 5.482
Authors: Weiva Sieh; Martin Köbel; Teri A Longacre; David D Bowtell; Anna deFazio; Marc T Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B Moysich; James D Brenton; Blaise A Clarke; Usha Menon; C Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Rayna K Matsuno; Susanne Krüger Kjær; Allan Jensen; Claus Høgdall; Kimberly R Kalli; Brooke L Fridley; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Louise A Brinton; Hannah P Yang; Mark E Sherman; Montserrat García-Closas; Jolanta Lissowska; Kunle Odunsi; Carl Morrison; Shashikant Lele; Wiam Bshara; Lara Sucheston; Mercedes Jimenez-Linan; Kristy Driver; Jennifer Alsop; Marie Mack; Valerie McGuire; Joseph H Rothstein; Barry P Rosen; Marcus Q Bernardini; Helen Mackay; Amit Oza; Eva L Wozniak; Elizabeth Benjamin; Aleksandra Gentry-Maharaj; Simon A Gayther; Anna V Tinker; Leah M Prentice; Christine Chow; Michael S Anglesio; Sharon E Johnatty; Georgia Chenevix-Trench; Alice S Whittemore; Paul D P Pharoah; Ellen L Goode; David G Huntsman; Susan J Ramus Journal: Lancet Oncol Date: 2013-07-09 Impact factor: 41.316
Authors: Friederike Hoellen; Athina Kostara; Thomas Karn; Uwe Holtrich; Ahmed El-Balat; Mike Otto; Achim Rody; Lars C Hanker Journal: Mol Clin Oncol Date: 2016-08-17